In reply [2]

Journal of Clinical Oncology

Volumn 24, Issue 28, 2006, Pages 4665-4666

  Chau, Ian ^a   Cunningham, David ^a   Tait, Diana ^a   Brown, Gina ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; NEUTROPENIC ENTEROCOLITIS; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION;

EID: 34247328645     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.2206     Document Type: Letter

References (17)

1. Chau I, Brown G, Cunningham D, et al: Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24:668-674, 2006
2. Mohiuddin M, Winter K, Mitchell E, et al: Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 24:650-655, 2006
3. Mohiuddin M, Regine WF, John WJ, et al: Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 46:883-888, 2000
4. Hartley A, Ho KF, McConkey C, et al: Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: Analysis of phase II/III trials. Br J Radiol 78:934-938, 2005
5. Machiels JP, Duck L, Honhon B, et al: Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: The RadiOxCape study. Ann Oncol 16:1898-1905, 2005
6. Ryan DP, Niedzwiecki D, Hollis D, et al: Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 24:2557-2562, 2006
7. Medical Research Council Oesophageal Cancer Working Party: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359:1727-1733, 2002
8. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
9. Bear HD, Anderson S, Smith RE et al: A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative T in patients wit operable carcinoma of the breast: Results of NSABP B-27. Breast Cancer Res Treat 88:S16, 2004 (abstr 26)
10. van Meerbeeck JP, Kramer G, van Schil PE et al: A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). J Clin Oncol 23:624s, 2005 (abstr 7015)
11. Gervais R, Ducolone A, Lechevalier T et al: Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) vinorelbine (Vr)-cisplatine (P): Final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer: Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol 23:625s, 2005 (abstr 7016)
12. Calais G, Pointreau Y, Alfonsi M et al: Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer: Preliminary results of GORTEC 2000-01. J Clin Oncol 24:281s, 2006 (abstr 5506)
13. Rutten H, Sebag-Montefiore D, Glynne-Jones R, et al: Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. J Clin Oncol 24: 2006 (abstr 3528)
14. Glynne-Jones R, Sebag-Montefiore D, Samuel L, et al: Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). J Clin Oncol 23:252s, 2005 (abstr 3527)
15. Schmoll HJ, Tabernero J, Nowacki M, et al: Final safety findings from a randomized phase III trial of capecitabine + oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. J Clin Oncol 24:163s, 2006 (abstr 3569)
16. Massuti B, Gomez A, Sastre J et al: Randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continuous infusion (FUFOX) as first line treatment in advanced or metastatic colorectal cancer (CRC). J Clin Oncol 24:165s, 2006 (abstr 3580)
17. Hochster HS, Hart LL, Ramanathan RK et al: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol 24:148s, 2006 (abstr 3510)